文献速递类风湿关节炎

德国RABBIT登记:类风湿关节炎患者在不同DMARD治疗下带状疱疹风险比较

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register.
PubMed 文献 · Ann Rheum Dis · 2021-07-28

结果显示tsDMARDs的暴露调整事件率最高(21.5/1000患者年),经年龄、性别和糖皮质激素调整及IPW加权后,tsDMARDs(HR 3.66,95%CI 2.38-5.63)、单克隆抗TNF抗体(HR 1.63,95%CI 1.17-2.28)和B细胞靶向治疗(HR 1.57,95%CI 1.03-2.40)相比csDMARDs带状疱疹风险显著升高。

要点

  • tsDMARDs治疗者带状疱疹暴露调整事件率最高(21.5/1000患者年)。
  • 调整后tsDMARDs的带状疱疹风险为csDMARDs的3.66倍(95%CI 2.38-5.63)。
  • 单克隆抗TNF抗体和B细胞靶向治疗也显著增加带状疱疹风险。

核心结论

  • 与csDMARDs相比,tsDMARDs治疗与带状疱疹风险增加3.6倍相关,bDMARDs治疗亦与带状疱疹风险升高相关。

主要发现

  • 共报告559例带状疱疹事件,发生于533例患者。
  • tsDMARDs的暴露调整事件率为21.5/1000患者年(95%CI 16.4-27.9),B细胞靶向治疗为10.3(95%CI 8.0-13.0),单克隆抗TNF抗体为9.3(95%CI 7.7-11.2),IL-6抑制剂为8.8(95%CI 6.9-11.0),可溶性TNF受体融合蛋白为8.6(95%CI 6.8-10.8),T细胞共刺激调节剂为8.4(95%CI 5.9-11.8),csDMARDs为7.1(95%CI 6.0-8.3)。
  • 经年龄、性别和糖皮质激素调整并采用IPW加权后,与csDMARDs相比,tsDMARDs的HR为3.66(95%CI 2.38-5.63),单克隆抗TNF抗体为1.63(95%CI 1.17-2.28),B细胞靶向治疗为1.57(95%CI 1.03-2.40)。

临床怎么用

  • 对于使用tsDMARDs、单克隆抗TNF抗体或B细胞靶向治疗的RA患者,应关注带状疱疹风险,必要时考虑预防措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare event and incidence rates of herpes zoster (HZ), also known as shingles, in patients with rheumatoid arthritis under treatment with conventional synthetic (cs), targeted synthetic (ts) or biologic (b) disease-modifying antirheumatic drugs (DMARDs). METHODS: Patients were prospectively enrolled from 2007 until October 2020. Reported HZ events were assigned to ongoing treatments or those terminated within 1 month prior to the HZ event. Exposure-adjusted event rates (EAERs) of HZ were calculated per 1000 patient years (py) and adjusted HRs with 95% CIs computed. Inverse probability weights (IPW) were used to adjust for confounding by indication. RESULTS: Data of 13 991 patients (62 958 py) were analysed, with 559 HZ events reported in 533 patients. The EAER of HZ was highest for tsDMARDs (21.5, 95% CI 16.4 to 27.9), followed by B cell targeted therapy (10.3, 95% CI 8.0 to 13.0), monoclonal antitumour necrosis factor (anti-TNF) antibodies (9.3, 95% CI 7.7 to 11.2), interleukin 6 inhibitors (8.8, 95% CI 6.9 to 11.0), soluble TNF receptor fusion protein (8.6, 95% CI 6.8 to 10.8), T cell costimulation modulator (8.4, 95% CI 5.9 to 11.8) and csDMARDs (7.1, 95% CI 6.0 to 8.3). Adjusted for age, sex and glucocorticoids and weighted with IPW, tsDMARDs (HR 3.66, 95% CI 2.38 to 5.63), monoclonal anti-TNF antibodies (HR 1.63, 95% CI 1.17 to 2.28) and B cell targeted therapy (HR 1.57, 95% CI 1.03 to 2.40) showed a significantly higher risk compared with csDMARDs. CONCLUSION: Our results provide evidence for a 3.6-fold increased risk of HZ associated with tsDMARDs and an increased risk of HZ under bDMARDs compared with csDMARDs.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Redeker I, Albrecht K, Kekow J, et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis. 2021. PMID: 34321218. doi:10.1136/annrheumdis-2021-220651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。